[1] RICHEL D J, VERVENNE W L. Systemic treatment of oesophageal cancer. 2004(3). doi:10.1097/00042737-200403000-00002
[2] MELUCH A A, GRECO F A, GRAY J R. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer:final results of a Minnie Pearl Cancer Research Network phase Ⅱ trial. 2003(4). doi:10.1097/00130404-200307000-00007
[3] CHOI N, PARK S D, LYNCH T. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma:mature results of phase Ⅱ study, 2004(1)
[4] URBA S G, ORRINGER M B, IANETTONNI M. Concurrent cisplatin,paclitaxel,and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. 2003(10). doi:10.1002/cncr.11759
[5] MURO K, HAMAGUCHI T, OHTSU A. A phase Ⅱ study of single-agent docetaxel in patients with metastatic esophageal cancer. 2004(6). doi:10.1093/annonc/mdh231
[6] PASINI F, de MANZONI G, PEDRAZZANI C. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy:dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin,docetaxel and concurrent radiotherapy. 2005(7). doi:10.1093/annonc/mdi207
[7] CONROY T, ETIENNE P L, ADENIS A. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus:response,toxicity,quality of life and survival. 2002(5). doi:10.1093/annonc/mdf063
[8] 傅剑华, 戎铁华, 李小东. 术前放化疗并手术治疗局部晚期食管癌Ⅱ期临床试验. 癌症2004(z11). doi:10.3321/j.issn:1000-467X.2004.z1.026
[9] KODAIRA T, FUWA N, KAMATA M. Single-institute phase Ⅰ/Ⅱ trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma, 2006(1B)
[10] JINGU K, NEMOTO K, MATSUSHITA H. Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. 2006. doi:10.1186/1471-2407-6-50
[11] EL-RAYES B F, SHIELDS A, ZALUPSKI M. A phase Ⅱ study of carboplatin and paclitaxel in esophageal cancer. 2004(6). doi:10.1093/annonc/mdh230
[12] McKEAGE M J. Lobaplatin:a new antitumour platinum drug. 2001(1). doi:10.1517/13543784.10.1.119
[13] MORGAN-MEADOWS S, MULKERIN D, BERLIN J D. A phase Ⅱ trial of gemcitabine,5-fluorouracil and leucovorin in advanced esophageal carcinoma. 2005(2). doi:10.1159/000087815
[14] WILLIAMSON S K, McCOY S A, GANDARA D R. Phase Ⅱ trial of gemcitabine plus irinotecan in patients with esophageal cancer:a Southwest Oncology Group (SWOG) trial, 2006(2)
[15] ASSERSOHN L, BROWN G, CUNNINGHAM D. Phase Ⅱ study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. 2004(1). doi:10.1093/annonc/mdh007
[16] JATOI A, MURPHY B R, FOSTER N R. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus,gastroesophageal junction and gastric cardia:a phase Ⅱ study from the North Central Cancer Treatment Group. 2006(1). doi:10.1093/annonc/mdj063
[17] LORENZEN S, DUYSTER J, LERSCH C. Capecitabine plus docetaxel every 3 weeks in first-and second-line metastatic oesophageal cancer:final results of a phase Ⅱ trial. 2005(12). doi:10.1038/sj.bjc.6602645
[18] BURGE M E, SMITH D, TOPHAM C. A phase I and Ⅱ study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. 2006(9). doi:10.1038/sj.bjc.6603084
[19] KAKLAMANOS I G, WALKER G R, FERRY K. Neoadjuvant treatment for respectable cancer of the esophagus and the gastroesophageal junction:a meta-analysis of randomized clinical trials. 2003(7). doi:10.1245/ASO.2003.03.078
[20] URSCHEL J D, VASAN H. A meta-analysis of randomized controlled trails that compared neoadjuvant chemoradiation and surgery to surger alone for respectable esophageal cancer. 2002(3). doi:10.1016/S0002-9610(2)00795-X
[21] FORSHAW M J, GOSSAGE J A, MASON R C. Neoadjuvant chemotherapy for oesophageal cancer:the need for accurate response prediction and evaluation. 2005(6). doi:10.1016/S1479-666X(5)80047-2
[22] BROWN W A, THOMA J, GOTLEY D. Use of oesophagogast roscopy to assess the response of oesphageal carcinoma to neoadjuvant therapy. 2004(2). doi:10.1002/bjs.4411
[23] WIEDER H A, BEER A J, LORDICK F. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. 2005(12)
[24] MARINKE WESTERTERP M D, HENDERIK L, van WESTREENEN M D. Esophageal cancer:CT,Endoscopic US,and FDG PET for assessment of response to neoadjuvant therapy-systematic revie. 2005. doi:10.1148/radiol.2363041042
[25] YANO M, TAKACHI K, DOKI Y. Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus, 2006(3)
[26] AKITA H, DOKI Y, MIYATA H. Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. 2006(5). doi:10.1002/jso.20501
[27] JIN J, LIAO Z, ZHANG Z. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. 2004(2). doi:10.1016/j.ijrobp.2004.03.033
[28] HENRY L R, GOLDBERG M, SCOTT W. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil,cisplatin,and paclitaxel before resection in localized esophageal cancer:a phase Ⅱ report. 2006(2). doi:10.1245/ASO.2006.01.001
[29] STAHL M, STUSCHKE M, LEHMANN N. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus, 2006(3)
[30] STAHL M, WILKE H, STUSCHKE M. Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. 2005(1). doi:10.1007/s00432-004-0604-5 |
